SwePub
Sök i LIBRIS databas

  Utökad sökning

L773:0163 4356 OR L773:1536 3694
 

Sökning: L773:0163 4356 OR L773:1536 3694 > Therapeutic Drug Mo...

Therapeutic Drug Monitoring of Ziprasidone in a Clinical Treatment Setting

Dolores Cherma Yeste, Maria (författare)
Linköpings universitet,Klinisk farmakologi,Hälsouniversitetet
Reis, Margareta (författare)
Linköpings universitet,Klinisk farmakologi,Hälsouniversitetet,Swedish National Board of Forensic Medicine
Hägg, Staffan (författare)
Östergötlands Läns Landsting,Linköpings universitet,Hälsouniversitetet,Klinisk farmakologi
visa fler...
Ahlner, Johan (författare)
Linköpings universitet,Klinisk farmakologi,Hälsouniversitetet
Bengtsson, Finn (författare)
Östergötlands Läns Landsting,Linköpings universitet,Hälsouniversitetet,Klinisk farmakologi
visa färre...
 (creator_code:org_t)
2008
2008
Engelska.
Ingår i: Therapeutic Drug Monitoring. - 0163-4356 .- 1536-3694. ; 30:6, s. 682-688
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • There is limited information on the pharmacokinetics of ziprasidone (ZIP) in naturalistic clinical settings. The objective of this study was to investigate the concentrations of ZIP and its active metabolite S-methyl-dihydroziprasidone (SMDZ), and the dose-normalized concentrations, using routine therapeutic drug monitoring (TDM) data. A high-performance liquid chromatographic method for determining serum concentrations of these substances for routine clinical use was established at the TDM Laboratory in Linkoping, Sweden. This analytical service was available to all physicians in Sweden. Between January 2001 and December 2004, 545 analyses, representing samples from 370 patients, were performed. The median daily ZIP dose was 120 mg (range 20-320 mg). In all, 121 steady-state trough specimens with essential clinical information were included in the pharmacokinetic evaluation. The median (25th to 75th percentile) serum concentration of ZIP was 125 nmol/L (82-188 nmol/L). The SMDZ:ZIP ratio decreased with increasing serum concentration of ZIP. The median (25th to 75th percentile) dose-normalized concentrations (nmol L-1 mg(-1) d(-1)) for ZIP and SMDZ were 1.13 (0.74-1.77) and 0.62 (0.45-0.86), respectively, with SMDZ:ZIP ratio of 0.57 (0.42-0.79). The overall coefficients of variation for close-normalized scruin concentrations of ZIP, SMDZ, and SMDZ:ZIP ratio were 62%, 56%, and 57%, respectively (n = 121). Smoking women had lower normalized ZIP concentrations than nonsmoking women. Twenty-eight patients with repeated eligible TDM analyses were studied for intraindividual variance over time. In summary, great interindividual and intraindividual differences in ZIP concentrations were observed. TDM of ZIP maybe used for individual dose adjustments and monitoring medication adherence.

Nyckelord

Antipsychotic agents
ziprasidone
therapeutic drug monitoring
serum concentration
naturalistic setting
MEDICINE
MEDICIN

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Sök utanför SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy